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Abstract
Deletions at chromosome 2p25.3 are associated with a syndrome consisting of intellectual
disability and obesity. The smallest region of overlap for deletions at 2p25.3 contains PXDN
and MYT1L. MYT1L is expressed only within the brain in humans. We hypothesized that sin-
gle nucleotide variants (SNVs) in MYT1L would cause a phenotype resembling deletion at
2p25.3. To examine this we sought MYT1L SNVs in exome sequencing data from 4, 296
parent-child trios. Further variants were identified through a genematcher-facilitated collabo-
ration. We report 9 patients with MYT1L SNVs (4 loss of function and 5 missense). The phe-
notype of SNV carriers overlapped with that of 2p25.3 deletion carriers. To identify the
transcriptomic consequences of MYT1L loss of function we used CRISPR-Cas9 to create a
knockout cell line. Gene Ontology analysis in knockout cells demonstrated altered expres-
sion of genes that regulate gene expression and that are localized to the nucleus. These dif-
ferentially expressed genes were enriched for OMIM disease ontology terms “mental
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retardation”. To study the developmental effects of MYT1L loss of function we created a
zebrafish knockdown using morpholinos. Knockdown zebrafish manifested loss of oxytocin
expression in the preoptic neuroendocrine area. This study demonstrates that MYT1L vari-
ants are associated with syndromic obesity in humans. The mechanism is related to dysre-
gulated expression of neurodevelopmental genes and altered development of the
neuroendocrine hypothalamus.
Author summary
Intellectual disability is defined by having an intelligence quotient of less than 70 points,
and it affects about 2–3 people in every 100. Obesity is defined as having a body mass
index of over 30 in adults or over the 95th centile in children. Both of these conditions are
major public health concerns in Western countries. Genetic studies have shown that small
missing pieces of chromosome (deletions, which remove many genes) and changes to the
lettering of genes (which stop the gene from working, mutations) can cause intellectual
disability or obesity. Here we identified 9 children with intellectual disability and obesity
who have mutations in a gene called MYT1L. This gene is thought to give an important
instruction for brain development. To find out what the effect of loss of MYT1L is on
brain development we reduced the levels of MYT1L (using a special chemical) in an exper-
imental zebrafish. This showed that loss of MYT1L in zebrafish causes a problem with the
development of the hypothalamus, which may explain how MYT1Lmutations cause obe-
sity in humans. In the zebrafish there was also reduction of a brain hormone called oxyto-
cin which is involved in thought processes, which may explain why MYT1Lmutations
cause intellectual disability. We have identified a new genetic condition caused by MYT1L
mutations, further study of this gene will help us understand, and treat, intellectual dis-
ability and obesity.
Introduction
Intellectual disability (ID) is defined by having a full-scale intelligence quota (IQ) of under 70,
causing difficulties with day to day functioning [1]. ID affects 2–3% of people and is a signifi-
cant public health concern as it is associated with substantial morbidity and mortality [1]. Obe-
sity is defined as a body mass index (BMI) of over 30 in adults or greater than the 95th centile
in children (CDC definition) [2]. Obesity affects around 30% of adults in the United States of
America and 10–20% of Europeans [2]. Obesity is associated with cardiovascular disease and
certain cancers [2].
Copy number variants (CNVs) and single nucleotide variants (SNVs) are a well-recognized
cause of ID [3]. 10–30% of individuals with ID will have a pathogenic CNV [3]. Exome
sequencing can detect pathogenic SNVs in around 30% of people with ID without a CNV [4].
Pathogenic CNVs and SNVs are also found in obesity, usually in association with a syndromic
presentation [5]. For example, both CNVs and SNVs of SIM1 are associated with obesity in
humans [6, 7]. In SIM1 deletion heterozygous mice there is impaired development of the para-
ventricular nucleus of the hypothalamus, with reduced melanocortin-4 receptor and oxytocin
expression, in association with hyperphagic obesity [8, 9].
Deletions at 2p25.3 are associated with a syndrome consisting of ID and obesity
[10,11,12,13,14]. The smallest region of overlap contains the PXDN and myelin transcription
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factor-1 like (MYT1L) genes [10]. Bi-allelic SNVs in PXDN are associated with congenital cata-
racts [15]. No CNVs containing only PXDN have been reported in DECIPHER in association
with ID. Thus PXDN is not a strong candidate gene for the phenotype associated with 2p25.3
deletions. SNVs in MYT1L have been reported in 2 children with ID [10]. MYT1L is a member
of the myelin transcription factor family, which is defined by the presence of a unique cystein-
cystein-histidine-cystein zinc finger domain [16]. MYT1L is a pro-neuronal transcription fac-
tor, and, in combination with other transcription factors can re-program fibroblasts into neu-
rons [17]. In vitro studies indicate that MYT1L functions as a transcriptional repressor [16].
The role of MYT1L in brain development is not well understood. However, myelin transcrip-
tion factor-1 (MYT1) has been shown to repress transcription in neuronal progenitor cells,
hence blocking Notch signaling and promoting neuronal differentiation [18]. Based upon its
biological function MYT1L is a strong candidate gene for ID.
Within certain deletion regions, there are single genes in which SNVs recapitulate the dele-
tion phenotype. For example, we recently demonstrated that 2p25.2 deletions and SNVs in
SOX11 present with Coffin-Siris syndrome [19]. Here we utilized exome-sequencing data from
4,296 parent-child trios in the Deciphering Developmental Disorders (DDD) study to demon-
strate that SNVs in MYT1L are associated with a phenotype resembling that of 2p25.3 deletions
with ID and obesity [4]. Through gene expression profiling of an MYT1L null cell line we show
that MYT1L regulates a network of transcription factors involved in neurodevelopmental disor-
ders. Knockdown of MYT1L orthologues in zebrafish resulted in altered hypothalamic oxytocin
expression, providing a potential mechanism for the obesity phenotype in humans.
Results
Exome sequencing identifies MYT1L variants in individuals with
intellectual disability
We identified 4 individuals with heterozygous de novo MYT1L variants through trio exome
sequencing performed as part of the Deciphering Developmental Disorders study and an addi-
tional 5 individuals with heterozygous de novo MYT1L variants through a genematcher facili-
tated collaboration (https://genematcher.org/)[20]. Table 1 and Fig 1 summarize the clinical
and genetic findings.
Patient 1 (DECIPHER ID 268494) is a 10 year old girl with intellectual disability and
autism. She was born at 31 weeks of gestation with bilateral talipes equinovarus and campto-
dactyly of the ring and middle fingers. Up until 5 years of age she had troublesome gastro-
esophageal reflux. She first sat at 12 months old. From age 6 years she could take single steps
with support. She requires a wheelchair and has never walked independently. She first said sin-
gle words at 5–6 years old and at 10 years old speaks in simple sentences. She has dysarthria.
She has had surgery for bilateral strabismus. Her parents reported hyperphagia and her BMI
was greater than the 99th centile. Comparative genomic hybridization (CGH) and SNRPN 15q
methylation (for Prader-Willi syndrome) were normal. Exome sequencing demonstrated a
frameshift variant in MYT1L (g.1926242CA>C, p.Leu381fs).
Patient 2 (DECIPHER 279017) is a 9 year old boy with intellectual disability who attends
a special needs school. Pregnancy and birth were unremarkable. He first spoke single words
at 15 months. On examination he was noted to have posterior plagiocephaly, 5th finger clino-
dactyly and an ataxic gait. He was not dysmorphic. His parents described him as having hy-
perphagia and his BMI was on the 96th centile. At age 9 he wears clothes for an 11–12 year
old. CGH was normal and brain magnetic resonance imaging (MRI) demonstrated cerebral
atrophy. Exome sequencing demonstrated a missense variant in MYT1L (g.1915795C>T,
p.Arg569Gln).
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Table 1. Summary of demographic features, developmental milestones, medical complications and exome sequencing of cohort.
Patient 1 Patient 2 Patient 3 Patient 4
Demographics F, 10 years M, 9 years M, 10 years F, 28 years
Whole exome
result
g.1926242CA>C
p.Leu381fs
g.1915795C>T
p.Arg569Gln
g.1915823G>A
p.His560Tyr
g.1915791C>T
Splice donor variant
OFC (cm) 55.6 cm (75th) 54.5 cm (75th) 54cm (42nd) 55cm (40th)
Ht (cm) 121.8 (0.4th) 146.7 (98th) 136.6 (50th) N/A
Weight (kg) 46.5 (98th) 43.4 (99th) 34.9 (75th) N/A
BMI >99th centile 96th centile 85th centile Dress size 22
Development Sitting 12 months
Single steps with support 6 years
Not walking independently
Single words 5 years
Single words 15
months
Sitting 18 months
Walked independently 24
months
Single words 5 years
Sitting 18 months
Single words 4 years
Non-ambulant (neural tube
defect)
Appetite Hyperphagia Hyperphagia Hyperphagia N/A
Pregnancy Born at 31 weeks, long period in SCBU, NGT
fed, floppy.
Normal Normal Normal
Tests CGH normal
MRI–white matter thinning SNRPN normal
EMG/NCS normal.
CGH normal
MRI–cerebral atrophy
CGH normal
MRI brain Normal
CGH normal
Other Bilateral congenital talipes
Bilateral squint
Autism
Mild gait ataxia anioshypermetropic
astygmatism
Self-mutilation
Neural tube defect
Hydrocephalus
Autism
Patient 5 Patient 6 Patient 7 Patient 8
Demographics F, 17 years F, 15 years F, 5 years F, 3 years
Whole exome
result
g.1921036A>G
p.Leu520Pro
g.1895856_1895865del
p.Thr741fs
g.1890345G>A
p.Arg839Ter
g.1921025G>T
p.His524Asn
OFC (cm) N/A 52.5 cm (2nd) 51.5 cm (25th) 51 cm (75th)
Ht (cm) 160 cm (25th) 163 cm (50th) 119cm (98th) 99cm (91st)
Weight (kg) 78.8 kg (98th) 59 kg (62nd) 30kg (99.6th) 16kg (98th)
BMI >99th centile 78th centile >99th centile 75th centile
Development Delayed speech
Motor delay
Delayed speech
Walked 22 months
Special school
Sat 9 months
Walked 19 months
Single words 2 years
Poor fine motor skills 5 years
Extra help at school
Sat 9 months
Walked 23 months
Running 36 months
No speech
Appetite Hyperphagia normal Hyperphagia normal
Pregnancy Normal Normal Normal normal
Tests CGH normal
MRI brain Normal
CGH normal Paternal 20p12 dup MRI: thin corpus callosum
Other Complex partial seizures from age 11 years
Autism
Hyperactive Hypotonia
Absence seizures
Autism
Patient 9 Patient 10
Demographics M, 13 years M, 27 months
Whole exome
result
c.1579G>A
p.Gly527Arg
2.3 Mb 2p25.3 deletion
OFC (cm) 53cm (25th) 50cm (50th)
Ht (cm) 149cm (40th) 80.5 cm (0.4th)
Weight (kg) 44kg (40th) 16kg (99.6th)
BMI 77th >99th centile
Development First sat 12 months
Walked 22 months
Single words 29 months
Not walking age 2
No speech
Appetite Normal Hyperphagia
(Continued )
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Patient 3 (DECIPHER ID 279061) is a 10 year old boy with intellectual disability, Attention
Deficit Hyperactivity Disorder (ADHD) and verbal dyspraxia. He sat at 18 months and walked
first at 2.5 years. He first said single words at 4–5 years old. At 10 years old he uses 2 word
phrases, but mainly communicates with sign language. He wears glasses for anioshypermetro-
piic astigmatism. He was described as having hyperphagia and his BMI was on the 85th centile.
CGH, fragile X, PWS testing and brain MRI were normal. Exome sequencing demonstrated
an MYT1Lmissense variant (g.1915823G>A, p.His560Tyr)
Patient 4 (DECIPER ID 276823) is a 28 year old woman with severe intellectual disability,
autism, self-injurious behavior and ADHD. She was born at 42 weeks of gestation with spina
bifida. She developed hydrocephalus in the first week of life. She has a ventricular shunt and
has required several procedures for shunt blockage. She sat at 18 months. She smiled at 3
weeks. She said single words at 4–5 years. She requires a wheelchair because of spastic parapar-
esis due to spina bifida. She is not dysmorphic. Her behavior is reported to be challenging,
including episodes of biting and pinching, triggered by excessive stimuli such as noise or
crowding. She has limited verbal communication, and uses communication aids. She can com-
prehend short (3 key phrases) sentences. Due to her level of disability she does not request or
seek food. However, when given food at mealtimes, she was noted to have a tendency to fill
her mouth excessively with food while eating. It was not possible to obtain weight or height.
However, she wears UK dress size 22 clothes (equivalent to dress size 20 in United States of
America, dress size 50 in Europe and dress size 24 in Australia). CGH was normal. Exome
sequencing demonstrated an MYT1L splice donor variant (g.1915791C>T).
Patient 5 is a 17 year old woman with intellectual disability and autism. She was born at 41
weeks gestation with no birth complications. Gross motor, fine motor and speech delay was
noted at 2 and 4 years old. She is noted to have dyslexia. She was not dysmorphic. She had
complex partial seizures from the age of 11 years old. She was reported to have hyperphagia
and BMI was greater than the 99th centile. CGH and brain MRI were normal. Whole genome
sequencing demonstrated an MYT1Lmissense variant (g.1921036A>G, p.Leu520Pro).
Patient 6 is a 15 year old girl with intellectual disability who attends a special needs school.
She first walked at 22 months old and had delayed speech. She was not dysmorphic. She did
not have hyperphagia and her BMI was on the 74th centile. CGH was normal. Exome sequenc-
ing demonstrated an MYT1L frameshift variant (g.1895856_1895865del, p.Thr741fs).
Patient 7 is a 5 year old girl with intellectual disability who required additional help at
school. She was born at term with no birth complications. She first sat at 9 months. She
walked first at 19 months. She required physiotherapy. She had speech delay, speaking single
words after 2 years of age. At 5 years old she had ongoing speech and language delay and was
reported to be clumsy. She was not dysmorphic. Eye examination demonstrated hyperopia
and strabismus. She had hyperphagia and her BMI was greater than the 99th centile. CGH
Table 1. (Continued)
Pregnancy Normal Normal
Tests CGH normal
MRI brain normal
N/A
Other Scoliosis
ADHD
Poor sleep
Abbreviations used: ADHD (Attention deficit hyperactivity disorder), OFC (orbitofrontal circumference), Ht (height) BMI (body mass index), CGH
(comparative genomic hybridization), MRI (magnetic resonance imaging), EMG (electromyography), NCS (nerve conduction studies), SCBU (special care
baby unit), NGT (nasogastric tube).
https://doi.org/10.1371/journal.pgen.1006957.t001
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demonstrated a 20p12 duplication, inherited from her phenotypically normal father. Exome
sequencing demonstrated an MYT1L nonsense variant (g.1890345G>A, p.Arg839Ter).
Patient 8 is a 3 year old girl with global developmental delay and autistic behaviour. She was
born at term with no pregnancy or birth complications. She had global hypotonia during the
first few months of life. She had global developmental delay. She first sat at 9 months of age,
walked independently at 2 years of age. At age 3 she had not developed speech, but used sign
language. At age 3 she was beginning to learn to run. She could draw a line and a circle. She
had absence seizures. Her BMI was on the 75th centile and hyperphagia was not present. MRI
Fig 1. Clinical characterization of MYT1L variant carriers. The heatmap depicts the frequency of various
clinical features in MYT1L variant carriers.
https://doi.org/10.1371/journal.pgen.1006957.g001
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brain demonstrated thinning of the corpus callosum. Exome sequencing demonstrated an
MYT1Lmissense variant (g.1921025G>T, p.His524Asn).
Patient 9 is a 13 year old boy with global developmental delay and ADHD. Pregnancy and
birth were unremarkable. Hypotonia and poor sleep were noted in the neonatal period. He
first sat at 12 months of age and walked at 22 months. He spoke single words at 29 months of
age. At 5 years old he knew 20 words, but had pronunciation difficulties. At 7 years old he
knew 50 words and was using 2-word sentences. At the age of 13 he was unable to read, write
or count. He attends a special educational needs school. His BMI was on the 68th centile. A
next generation sequencing gene panel test demonstrated an MYT1Lmissense variant
(c.1579G>A, p.Gly527Arg).
The MYT1L gene is constrained for missense and protein truncating
variants
Protein truncating variants (PTV) in developmentally crucial genes should occur less frequently
than predicted in individuals without developmental disorders. The expected frequency of PTV
in human genes has been reported in the ExAC database based upon parameters such as muta-
tion rates for given nucleotide bases [21]. We identified only a single loss of function variant in
MYT1L in the ExAC database (accessed March 2017) [21]. This is compared to an expected
number of 33 loss of function variants, giving a probability of loss of function intolerance score
of 1.0 (a probability of loss of function intolerance score>0.9 indicates intolerance to loss of
function). In addition, 205 missense variants were reported, compared to an expected 402.5
missense variants (Z score = 4.81, indicating constraint on variation). The Provean (median
-5.2 [interquartile range -6.0 - -3.85] vs -1.1 [interquartile range -2.59 - -0.43], Mann-Whitney
U-test, u = 344, z = -2.96, p = 0.012) and SIFT (median 0.001 [interquartile range 0.005–0.28] vs
0.068 [interquartile range 0.0003–0.003], Mann-Whitney U-test, u = 569, z = -2.61, p = 0.025)
scores for the missense variants in our patients were significantly higher than the scores for
ExAC missense variants (Fig 2A). This indicates substantial constraint on both PTV and mis-
sense variants. This supports a pathogenic role for PTV and missense variants in the reported
phenotype. In addition, an in silico model of the structural effects of the MYT1Lmissense vari-
ants indicated that they were likely to interfere with DNA binding (Fig 2B).
The phenotype of MYT1L variant carriers resembles that of 2p25.3
microdeletion patients
To examine the hypothesis that haploinsufficiency for MYT1L drives the 2p25.3 deletion syn-
drome, we compared the phenotype of 2p25.3 deletion carriers with those of MYT1L single nucle-
otide variant (SNV) carriers. The phenotypes associated with deletion of 2p25.3 were defined by
a literature review [10, 11, 12, 13, and 14] and we report an unpublished case (patient 10 in
Table 1). The smallest region of overlap contains PXDN and MYT1L. No PXDN SNVs were iden-
tified in the DDD exome dataset. Using Fischer’s exact test there was no significant difference
between the proportions of deletion or SNV patients with the following phenotypes: intellectual
disability, gross motor delay, speech delay, autism, overweight/obese or hyperphagia. This sup-
ports our hypothesis that MYT1L haploinsufficiency is central to the 2p25.3 deletion phenotype.
Expression of MYT1L occurs in brain regions relevant to the human
disease phenotype
Given the phenotype of intellectual disability and predisposition to overweight/obesity we rea-
soned that MYT1L should be expressed in relevant neuroanatomical structures. We first
MYT1L mutations cause intellectual disability and obesity
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confirmed that MYT1L expression is confined to the brain and pituitary in humans using the
GTEx Portal (accessed March 2017) [22]. We then utilized the Allen Brain atlas to examine the
spatial expression pattern of MYT1L in human brain [23].
Fig 2. Structural effects of MYT1L missense variants. (A)Schematic diagram of MYT1L protein, the yellow
boxes indicate zinc finger domains. The missense variants are indicated by arrows. (B)Model of the 2nd and
3rd zinc fingers of MYT1L bound to DNA. This is based upon the structure of the 4th and 5th zinc fingers of
MYT1 (protein data bank file 2mf8), which have high sequence similarity to the 2nd and 3rd zinc fingers of
MYT1L. The second zinc finger is in magenta, and the third finger in green. The beige spheres represent the
zinc ions, with the CCHC zinc ligands shown in cyan. Replacement of L520 by proline is expected to disrupt
the structure of the protein by preventing the formation of a tight turn. H524 and G527 are a zinc ligands, so
replacement will also disrupt the structure. H560 and R569 are conserved residues directly involved in DNA
binding. Image created using Pymol.
https://doi.org/10.1371/journal.pgen.1006957.g002
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In keeping with a role in cognition/intellectual disability, MYT1L is expressed at signifi-
cantly higher levels in the adult cerebral cortex than in the hippocampus, basal ganglia and
hypothalamus (Mann-Whitney U-test, P<0.001)(Fig 3A). We could not demonstrate signifi-
cant expression of MYT1L in hypothalamic structures relevant to appetite and obesity in the
adult brain.
We then hypothesized that MYT1Lmight be expressed in hypothalamic structures relevant
to appetite and obesity during brain development. Data from the prenatal LMD microarray
from the Brainspan atlas of the developing human brain demonstrated that MYT1Lwas
expressed in multiple hypothalamic structures at 15–16 post conception weeks (pcw), with sig-
nificant reduction in expression at 21 pcw (Mann-Whitney U-test, p<0.001)(Fig 3B). This
suggests that MYT1L principally plays a role in hypothalamic development rather than postna-
tal hypothalamic function.
Loss of MYT1L expression dysregulates expression of genes involved in
neurodevelopmental disorders
To study the transcriptional consequence of loss of MYT1L function we created a Human
Embryonic Kidney (HEK) null cell line using CRISPR-Cas9. Sanger sequencing of genomic
DNA confirmed creation of homozygous premature stop codons in MYT1L. Gene expression
profiling using the Clariom S array identified 955 differentially expressed genes (2-fold expres-
sion change, false discovery rate 2%). Enrichment analysis (using Enrichr http://amp.pharm.
mssm.edu/Enrichr/) [24]demonstrated that the differentially expressed gene set was enriched
for the Gene Ontology Biological Process 2015 term gene expression (GO:0010467, adjusted
p-value 0.00077, Z-score -2.34, combined score 16.77)(Fig 4A) and Gene Ontology Cellular
Component 2015 terms nucleolus (GO: 0005730, adjusted p-value 0.0023, Z-score -2.21, com-
bined score 13.43) and nucleoplasm (GO: 0005654, adjusted p-value 0.005853, Z-score -2.08,
combined score 11.4) (Fig 4B). The gene set was also enriched for the Reactome 2016 pathways
Gene Expression_Homo Sapiens_R-HAS-74160 (adjusted p-value 2.2 x 10–7, Z-score -2.16,
combined score 33) and Generic Transcription Pathway_Homo Sapiens_R-HAS-212436
(adjusted p-value 0.01586, Z-score -2.26, combined score 9.35)(Fig 4C). The differentially
expressed genes were also enriched for genes from the OMIM disease ontology term mental
retardation (p-value 0.045, adjusted p-value 0.38, Z-score -1.32, combined score 1.27)(Fig 4D).
This suggests that MYT1L regulates a network of genes that control transcription, and which
have themselves been implicated in the etiology of neurodevelopmental disorders.
The zebrafish MYT1L orthologs (myt1la and myt1lb) are expressed only
in the central nervous system
Given the obesity phenotype in patients with MYT1L SNVs we hypothesized that loss of
MYT1L function may interfere with development of the neuroendocrine hypothalamus. We
sought to explore this by creating a zebrafish knockdown model. MYT1L has two orthologs in
zebrafish: myt1la and myt1lb. By using whole mount in situ hybridization (WISH) we demon-
strate that both orthologs are expressed diffusely within the zebrafish central nervous system,
including the hypothalamus, and not within any extra-neuronal tissues (Fig 5A). This resem-
bles the expression pattern in humans.
Loss of sim1 function results in reduced myt1la expression in zebrafish
ANRT2 encodes a dimerization partner required for SIM1 function in hypothalamic develop-
ment. To examine the role of SIM1-ARNT2 in regulating myt1la/mytl1bwe performed WISH
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Fig 3. MYT1L expression in human brain. (A) MYT1L expression levels are significantly higher in the frontal
cortex than hippocampus, basal ganglia or hypothalamus in adult brain (p<0.001). Data presented as median z-
score +/- 95% confidence interval. (B) MYT1L expression levels in the developing hypothalamus are significantly
higher at 15–16 post conception weeks than 21 post conception weeks (p<0.001). The labels on the x-axis with 21
indicate expression at 21 post conception weeks, the x-axis labels without 21 indicate expression at 15–16 weeks.
Data presented as median z-score +/- 95% confidence interval AHN = anterior hypothalamic nucleus.
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for myt1la in the previously described homozygous arnt2hi2639Tg null zebrafish [25]. In the
mutant zebrafish myt1la was undetectable in the hypothalamus (Fig 5B). This shows a role for
SIM1-ARNT2 dimers in regulating myt1la expression in the hypothalamus. These experiments
demonstrate that MYT1L lies downstream of SIM1-ARNT2 in the leptin-melanocortin-SIM1
pathway, and, in turn, MYT1L regulates OXT expression in the hypothalamus.
Knockdown of myt1la/myt1lb causes altered hypothalamic development
in zebrafish
Antisense morpholinos (MO) targeting myt1la or myt1lb, alone or in combination, were
injected into zebrafish embryos at the 1- or 2-cell stage. The amount of MO injected was kept
constant. WISH using probes against oxytocin (OXT) or arginine vasopression (AVP) was per-
formed. MO targeting myt1la or myt1lb resulted in an almost complete loss of OXT in the neu-
roendocrine pre-optic area (Fig 5C and 5D). MO targeting myt1la or myt1lb also resulted in an
almost complete loss of AVP in the neuroendocrine pre-optic area, but not in the ventral hypo-
thalamus (Fig 5E and 5F). This suggests that myt1la and myt1lb may play a specific role in reg-
ulating the development of the neuroendocrine hypothalamus.
Discussion
Here we describe 9 individuals with de novo SNVs in MYT1L. These individuals shared several
phenotypic features. All had global developmental delay or intellectual disability. Gross motor
delay was present in all, and patient 1 had not walked independently by the age of 10 years old.
Patient 4 also required a wheelchair, but this was related to spastic paraparesis secondary to
spina bifida. No other individuals with CNVs or SNVs of MYT1L have been reported with a
neural tube defect. The spina bifida in patient 4 is likely etiologically unrelated to the MYT1L
SNV. Six of the MYT1L SNV carriers were overweight or obese based upon BMI centiles and
patient 4 requires a dress size 22, implying obesity. Five of the patients had hyperphagia, but
patient 4 did not have sufficient speech development or motor function to ask for or take food.
Three had a diagnosis of an autism spectrum disorder. There was no shared, distinctive facial
dysmorphology. Two MYT1L SNV carriers have been reported by De Rocker et al: patient 14
had developmental delay, autism and was described as obese (BMI not reported), patient 15
had developmental delay, autism and BMI>97th centile [10]. An autistic male with develop-
mental delay and febrile seizures in association with an MYT1L nonsense mutation was
reported by Wang et al [26], however BMI was not described in this paper. There was no sig-
nificant difference in the frequency of phenotypic features between 2p25.3 deletion and
MYT1L SNV carriers. This suggests that haploinsufficiency for MTY1L drives the 2p25.3 dele-
tion phenotype. Our report confirms that CNVs and SNVs of MYT1L are associated with a
syndromic presentation consisting of developmental delay/ID, hyperphagia and obesity.
The clinical presentation of MYT1LCNV and SNV carriers overlaps with other mendelian
causes of obesity. Prader-Willi syndrome (PWS) is a well-recognized cause of hyperphagic
obesity [27]. The presence of characteristic dysmorphology and hypogenitalism may help dif-
ferentiate PWS from MYT1L SNV/CNV carriers [27]. Deletions and SNVs of SIM1 are associ-
ated with hyperphagic obesity [6, 7], with developmental delay associated with 6q14.1
deletions [7]. Bi-allelic SNVs of leptin (LEP) [28], leptin receptor (LEPR) [29], and pro-
DMHN = dorsomedial hypothalamic nucleus. LHA = lateral hypothalamic area. MMN = medial mammillary nucleus.
PHN = posterior hypothalamic nucleus. PVN = paraventricular nucleus. VMHN = venteromedial hypothalamic
nucleus.
https://doi.org/10.1371/journal.pgen.1006957.g003
MYT1L mutations cause intellectual disability and obesity
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006957 August 31, 2017 11 / 23
Fig 4. Gene expression profiling of MYT1L knockout cell line. (A)Enrichment analysis demonstrates enrichment for
Gene Ontology Biological Process 2015 term gene expression (GO:0010467, adjusted p-value 0.00077, Z-score -2.34,
combined score 16.77). (B)Enrichment analysis demonstrates enrichment for Gene Ontology Cellular Component 2015
terms nucleolus (GO: 0005730, adjusted p-value 0.0023, Z-score -2.21, combined score 13.43) and nucleoplasm (GO:
0005654, adjusted p-value 0.005853, Z-scre -2.08, combined score 11.4). (C)Enrichment analysis demonstrates enrichment
MYT1L mutations cause intellectual disability and obesity
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opiomelanocortin (POMC) [30] are also associated with hyperphagic obesity. LEP and LEPR
can be distinguished from MYT1L due to the association of hypogonadotrophic hypogonad-
ism with LEP and LEPR SNVs. Patients with POMC deficiency present with a range of endo-
crine problems not reported in association with MYT1L variants. There is also phenotypic
overlap between certain microdeletion syndromes and MYT1L. Smith-Magenis syndrome
(17p11.2 deletion) is associated with developmental delay and variable obesity [31]. Facial dys-
morphology, sleep disturbance and self-injurious behavior reported in Smith-Magenis syn-
drome were not identified in our MYT1L cohort. 22q11.2 deletion carriers have increased
rates of obesity [32], and the presence of cleft lip/palate, congenital heart disease or parathyroid
disease can permit distinction from MYT1L variant carriers.
Our data supports the hypothesis that MYT1L SNVs cause loss of protein function and hap-
loinsufficiency. Data from the ExAC indicated a loss of function intolerance score of one,
which indicates that MYT1L is a haploinsufficient gene that will not tolerate heterozygous loss
of function variants. Four of the SNVs we report were predicted to be PTV, which would result
in loss of protein function. In silico modelling indicates that the 5 missense variants we report
would be predicted to interfere with the binding of MYT1L to DNA. Both p.His560Tyr and p.
Arg569Gln affect conserved amino acids that directly bind to DNA. These variants are likely
to disrupt DNA binding. The p.Leu520Pro variant lies at a protein loop which is crucial for the
correct folding of the second zinc finger domain; this missense variant is likely to disrupt pro-
tein structure and hence DNA binding. His524 and Gly527 are zinc ligands, and any change
will disrupt protein structure. The fact that the phenotypes of 2p25.3 deletions and MYT1L
SNVs overlap supports haploinsufficient loss of function of MYT1L as the disease mechanism.
By GEP in an MYT1LHEK cell line with homozygous MYT1L frameshift variants, we demon-
strate altered expression of multiple genes implicated in regulation of gene expression and
transcription. Haploinsufficiency for MYT1L has clear potential to disrupt expression of criti-
cal genes during brain development and hence cause a neurodevelopmental disorder.
The expression pattern of MYT1L in the human brain reflects the clinical features of indi-
viduals with 2p25.3 deletions and MYT1L SNVs. The widespread expression of MYT1L in
brain structures relevant to cognition supports a role for loss of function in the etiology of ID.
This is in keeping with the fact that the overwhelming majority of ID and autism genes have
widespread expression in the cerebral cortex [33]. The expression pattern of MYT1L in human
brain also supports a role for the gene in appetite/obesity. MYT1Lwas expressed in multiple
hypothalamic nuclei at 15–16 pcw, with significant reduction in expression at 21 pcw. This
leads us to hypothesise that MYT1Lmay play a role in the development of the hypothalamus,
and that MYT1L loss of function may be associated with obesity by impairing development of
hypothalamic nuclei. Similar mechanisms operate for other obesity genes such as SIM1 [8, 9].
To investigate a role for myt1la/b in development of the neuroendocrine hypothalamus we
generated a knockdown model in zebrafish. Injection of MO against myt1la or myt1lb, alone
or in combination, resulted in a severe loss of expression of OXT in the neuroendocrine preop-
tic area. Knockdown of myt1la/b resulted in loss of AVP expression in the neuroendocrine pre-
optic area but not the ventral hypothalamus. This suggests that myt1la/bmay influence the
development of the neuroendocrine preoptic area, but not other regions of the hypothalamus.
The neuroendocrine preoptic area is the functional equivalent of the paraventricular nucleus
for Reactome 2016 pathways Gene Expression_Homo Sapiens_R-HAS-74160 (adjusted p-value 2.2 x 10–7, Z-score -2.16,
combined score 33) and Generic Transcription Pathway_Homo Sapiens_R-HAS-212436 (adjusted p-value 0.01586, Z-score
-2.26, combined score 9.35). (D)Enrichment analysis demonstrates enrichment for OMIM disease term mental retardation (p-
value 0.045, adjusted p-value 0.38, Z-score -1.32, combined score 1.27).
https://doi.org/10.1371/journal.pgen.1006957.g004
MYT1L mutations cause intellectual disability and obesity
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006957 August 31, 2017 13 / 23
Fig 5. Hypothalamic peptide expression in zebrafish knockdown for MYT1L orthologues. (A)Whole mount in
situ hybridization demonstrating that MYT1L orthologs myt1la and myt1lb are expressed throughout the zebrafish
central nervous system. T = telencephalon, te = tectum, hy = hypothalamus, h = hindbrain. (B)Whole mount in situ
hybridization demonstrating loss of myt1la expression in arnt2 mutant zebrafish, top panel shows control fish and
bottom panel arnt2 mutant fish. The embryos are heavily over-stained to show the low-level expression of myt1la in
the ventral diencephalon. The arrow indicates the region of the neuroendocrine preoptic area where oxytocin
MYT1L mutations cause intellectual disability and obesity
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in humans [34]; lesions of which cause hyperphagic obesity [7, 8]. Thus, MYT1LCNVs and
SNVs may lead to hyperphagic obesity by impairing hypothalamic development.
SIM1, functioning with its dimerization partner ARNT2, regulates the development of the
paraventricular nucleus [7, 8]. SIM1 deletion heterozygous mice have hypocellularity of the
paraventricular nucleus and hyperphagic obesity [7, 8]. To examine an interaction of SIM1
with MYT1Lwe performed WISH for myt1la in the homozygous arnt2hi2639Tgnull zebrafish,
which has no functional arnt2 and hence disruption of sim1a/b function. The absence of
myt1la expression in the neuroendocrine preoptic area demonstrates that MYT1L lies down-
stream of SIM1-ARNT2 in hypothalamic development. Our experiments also indicate that
OXT is downstream of MYT1L. This suggests that loss of OXT may be a final common path-
way in genetic forms of obesity, and represent a treatment target in multiple disorders.
In summary, we have identified a series of individuals with MYT1L de novo SNVs who pres-
ent with a syndrome of ID and obesity. Genes involved in nucleosome remodeling, especially
those of the neuron-specific Brg1/hBrm Associated Factor (nBAF) complex, have emerged as
being central to the pathogenesis of ID [35]. However, MYT1L is not known to play a role in
nucleosome remodeling, and GEP did not demonstrate that genetic pathways involved in
nucleosome remodeling are dysregulated in MYT1L knockdown cells. This suggests that the
ID observed in patients with MYT1L SNVs and CNVs is not related to altered nucleosome
remodeling. The mechanism by which MYT1L loss of function results in ID is unclear. Murine
studies of MYT1 demonstrate that it promotes neuronal differentiation of neuronal progenitor
cells by inhibiting Notch signaling [18]. It seems reasonable to suggest that MYT1Lmay per-
form a similar function in the developing brain and that loss of MYT1L function will disrupt
this process. The obesity phenotype with MYT1L loss of function is associated with disrupted
development of the neuroendocrine hypothalamus in zebrafish, manifested by loss of OXT.
This is similar to the effects of SIM1 [8, 9] and POU3F2 loss of function [24], both of which are
associated with hyperphagic obesity. OXT is emerging as a key neurochemical in both autism
and obesity pathogenesis. Polymorphisms in OXT and its receptor are associated with autism
risk, and intranasal OXT improves autism symptoms and imaging abnormalities [36, 37]. OXT
treatment reduces food intake in humans and in sim1 mutant mice [38, 39]. In conclusion, we
identify MYT1Lmutations as a cause of syndromic obesity, and establish MYT1L as a member
of the leptin-melanocortin-SIM1 pathway, with downstream loss of OXT associated with
MYT1Lmutations a potential therapeutic target.
Methods
Exome sequencing
For probands and their parents in the DDD study, saliva samples were collected (Oragene
DNA collection kits, DNA Genotek, Kanata, ON, Canada) and DNA extracted (QIAsymph-
ony, Qiagen, Venlo, Netherlands). Exome sequencing was performed at the Wellcome Trust
Sanger Institute with Agilent SureSelect 55MB Exome Plus with Illumina HiSeq to investigate
expressing neurons are located. (C)Whole mount in situ hybridization demonstrating that knockdown of myt1la and
myt1lb, alone or in combination, results in loss of oxytocin expression in the neuroendocrine preoptic area. Arrows
indicate neuroendocrine preoptic area. (D)Bar chart quantifying loss of oxytocin expression in neuroendocrine
preoptic area. WISH for oxytocin was quantified as follows: ~30 cells = wild type expression, 5–15 cells = reduced,
1–4 = highly reduced, 0 = no expression (E)Whole mount in situ hybridization demonstrating that knockdown of
myt1la/b results in loss of arginine vasopressin expression in the neuroendocrine preoptic region (indicated by arrow)
but not the ventral hypothalamus (indicated by arrowhead). (F) Bar chart quantifying loss of arginine vasopression
expression in myt1la/b morphants. WISH for arginine vasopressin was quantified as follows: ~30 cells = wild type
expression, 5–15 cells = reduced, 1–4 = highly reduced, 0 = no expression.
https://doi.org/10.1371/journal.pgen.1006957.g005
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single nucleotide variants (SNVs) and small insertion-deletions (indels) in coding regions of
the genome. An automated variant pipleline was used as previously described [4]. Probands
were identified with protein altering SNVs in MYT1L.
Genome sequencing
Blood samples were sent for sequencing at the HudsonAlpha Genomic Services Laboratory
(http://gsl.hudsonalpha.org). Genomic DNA was isolated from peripheral blood and WGS was
conducted to a mean depth of 35X, with >80% of bases covered at 20X. WGS was done on
Illumina HiSeq Xs. Reads were aligned and variants called according to standard protocols
[40, 41]. A robust relationship inference algorithm (KING) was used to confirm familial rela-
tionships [42]. Using filters related to call quality, allele frequency, and impact predictions, we
searched for rare, damaging de novo variation, or inherited X-linked, recessive, or compound
heterozygous variation in affected probands. WGS were carried out under a research protocol
and were not completed within a CAP/CLIA laboratory. All variants found to be medically rel-
evant and returnable were validated by Sanger sequencing in an independent CLIA laboratory
(Emory Genetics Laboratory) before being returned to participants, although these validated
variant results are not CLIA-compliant as the input DNA was originally isolated in a research
laboratory. Ethics approval and consent to participate: Review boards at Western (20130675)
and the University of Alabama at Birmingham (X130201001) approved and monitored this
study. Consent for publication: A parent or legal guardian was required to give consent to par-
ticipate in the study and inclusion of their data for publication, and assent was obtained from
those children who were capable.
Ethics statement
The study has UK Research Ethics Committee approval (10/H0305/83, granted by the Cam-
bridge South REC, and GEN/284/12 granted by the Republic of Ireland REC). Written consent
taken from all participants and declaration of Helsinki followed.
In silico assessment of MYT1L variant pathogenicity
The predicted effect of the MYT1Lmissense variants was examined using SIFT and PolyPhen.
Evolutionary conservation of mutated amino acids was assessed by aligning orthologs in
Ensembl (http://www.ensembl.org/index.html). The presence of MYT1L variants in control
populations and MYT1L constraint metrics were queried using the ExAC browser (http://exac.
broadinstitute.org/gene/ENSG00000186487). SNVs are reported using MYT1L Isoform-1
(canonical sequence, 1 186 amino acids) and ensemble transcript ENST00000428368(http://
www.ensembl.org/Homo_sapiens/Transcript/Summary?g=ENSG00000186487;r=2:1791242-
2331116;t=ENST00000428368).
To investigate the structural effects of the MYT1Lmissense variants, we generated a
3-dimensional model of the 2nd and 3rd zinc finger domains of MYT1L bound to DNA. This
was based upon the structure of MYT1 4th and 5th zinc finger domains. The amino acid
sequence of MYT1 was first extracted from the report of Gamsjaeger et al [43]. The 4th and 5th
zinc finger domains of MYT1 and 2nd and 3rd zinc finger domains of MYT1L aligned well,
indicating that the structure of MYT1 is suitable to model the effects of MYT1L missense vari-
ants. A 3-dimensional model of the 4th and 5th zinc finger domains of MYT1 bound to DNA
was then generated using Pymol (https://www.pymol.org/). The MYT1Lmissense variants
were placed at the appropriate residues of this to visualize the structural and hence potential
functional, consequences.
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Generation of frameshift mutations in MYT1L using CRISPR in HEK cell
line
Human embryonic kidney (HEK) cell line HEK-293 (HD PAR-617, ATCC CRL-1573)
was confirmed to be triploid at the MYT1L locus using SNP 6.0 arrays. MYT1L transcript
ENST00000399161 was targeted. A guide RNA (gRNA1240) was designed to bind at exon 9 of
MYT1L, with an adjacent protospacer adjacent motif (PAM) site. HEK-293 cultures were
transfected with gRNA1240. Colonies were then genotyped by PCR to identify those with
homozygous out of frame variants at the gRNA1240 site. PCR sequencing of genomic DNA
demonstrated a 1 base pair insertion of a thymidine base within the gRNA1240 site at allele 1
and 2. PCR sequencing demonstrated a 10 base pair deletion in allele 3. Long range PCR did
not reveal any larger deletions across the gRNA site. These sequence variants are predicted to
cause a downstream STOP codon at amino acid 115 and 170, respectively.
Gene expression profiling (GEP)
RNA was extracted using trizol and a standard column based system from the isogenic paren-
tal HEK-293 line and the knockout line, each in biological triplicate. Whole genome gene
expression profiling was performed using the Clariom S array (affymetrix). Differentially
expressed genes were defined as those showing a 2 fold or greater change in expression with a
false discovery rate of 2% using the Affymetrix Transcriptome analysis console. Enrichment
analysis was performed using Enrichr (http://amp.pharm.mssm.edu/Enrichr/) with a crisp
gene set (i.e. no fold change expression assigned to each gene) [24].
In silico assessment of MYT1L expression pattern in human brain
The expression pattern of MYT1L in adult brain was examined using the Allen brain atlas
(microarray data using Agilent 8x60K cDNA chip) [23]. Expression data (Z score normalized)
were downloaded for 6 adult brains (donor id 9861, 10021, 12876, 14380, 15496 and 15697)
for the frontal cortex, hippocampus, basal ganglia and hypothalamus (at least 3 regions from
each anatomical site). Expression levels were compared between each anatomical site using
Mann-Whitney U-tests. The expression pattern of MYT1L in developing human brain was
examined using the brainspan atlas. Microarray data (Z score normalized) was downloaded
from 2 donor brains at 15–16 post conception weeks (pcw) (donor id 12840 and 14751) and 2
donor brains at 21 pcw (donor id 12566 and 12690) for the paraventricular nucleus, anterior
hypothalamic nucleus, lateral hypothalamic area, dorsomedial hypothalamic area, venterome-
dial hypothalamic area, posterior hypothalamic nucleus and medial mammillary nucleus.
Mann-Whitney U-tests were used to compare median MYT1L expression in each hypotha-
lamic nucleus at 15–16 pcw and 21 pcw.
Generation of zebrafish myt1la/b knockdown
Zebrafish (Danio rerio) were raised, maintained and crossed as described [43]]. Development
of embryos was at 28˚C, and staging was determined by both hours post fertilization (hpf) and
morphological characteristics [44]. Embryos were genotyped for the arnt2hi2639cTg allele as pre-
viously described [25]. All procedures were in accordance with NIH guidelines on the care
and use of animals and were approved by the Georgetown University Institutional Animal
Care and Use Committee, Protocol 11–008.
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Templates, probes and Whole-Mount In Situ Hybridization (WISH)
Whole-Mount In Situ Hybridization (WISH) using DIG-labeled riboprobes was performed
as previously described [44]. Zebrafish myt1la and myt1lb templates were generated by PCR
amplification from 2 dpf zebrafish cDNA and then cloned into pJET1.2 vectors in “backwards”
direction. The myt1a exon 5 primers were 1aF:CACCACGACAATTATTCTAGTG, and 1aR:
CTTTAGGGTAGTAAGCTC. The myt1b exon four primers were 1bF: AGAGTGACCATAT
GAATTGCA, and 1bR: CTGCTGCTGGTTATTGTTGAG. The plasmids were linireized with
XbaI and probe was synthesized using T7 RNA polymerase and reagents from the DIG label-
ing kit (Roche).
Morpholino oligonucleotide (MO) injections
MO injections for sim1 were used as previously published [45]. For the myt1la and myt1lb
genes, two MOs for each gene were used to knockdown these proteins. One MO was designed
to block translation and the other was designed to block splicing. The following MOs were
synthesized by Gene-Tools, LCC: myt1la ATG MO, 5’-ACCTCCATCTGAATGCAGTGG
TTGA; myt1la Splice MO, 5’-GGACAGCTGGAGACAAGAGAAATAA; myt1lb ATG MO,
5’-CATCTGCTACATCCACCTCCATCTG; myt1lb Splice MO, 5’-ATATTTGTGCCCTCAC
CTATTTCAT; and tp53 MO, 5’- GCGCCATTGCTTTGCAAGAATTG. The Standard Con-
trol MO from Gene Tools was used as control. Solutions consisting of 4 ng/nl MO plus
0.5% tetramethyl rhodamine dextran in dH20 were microinjected into one to four cell stage
embryos.
Images were acquired using a Zeiss Axioplan2 microscope fitted with an AxioCam camera
using AxioVision software, or, with a Zeiss stereoscope fitted with a Canon Oneshot digital
camera. Digitized images were imported into PhotoShop CS (Adobe Systems Inc, San Jose,
CA), contrast and brightness adjusted as necessary. WISH for myt1la/b expression was quanti-
fied using an ordinal scale: 0 = no staining, 1 = dramatically reduced staining, 2 = normal
staining. WISH for oxytocin was quantified as follows: ~30 cells = wild type expression, 5–15
cells = reduced, 1–4 = highly reduced, 0 = no expression.
Statistical analysis
Statistical differences in green fluorescent protein (GFP) expression in 2 somite embryos was
determined using ANOVA, followed by Tukey post-hoc tests for individual groups. Signifi-
cance of MO induced phenotype categories was evaluated by Ordinal Logistic Regression. The
statistical analyses utilized SPSS (version 22) from IBM.
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